X0306 4 2019-11-06 false 0001434418 CONSTELLATION PHARMACEUTICALS INC CNST 0001680329 Reeve Emma C/O CONSTELLATION PHARMACEUTICALS, INC. 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142 false true false false Chief Financial Officer Common Stock 2019-11-06 4 M false 56542.00 6.61 A 56542.00 D Common Stock 2019-11-06 4 M false 9084.00 7.60 A 65626.00 D Common Stock 2019-11-06 4 S false 2574.00 16.3088 D 63052.00 D Common Stock 2019-11-06 4 S false 4158.00 17.5945 D 58894.00 D Common Stock 2019-11-06 4 S false 24264.00 18.4025 D 34630.00 D Common Stock 2019-11-06 4 S false 6188.00 19.2047 D 28442.00 D Common Stock 2019-11-06 4 S false 11976.00 20.0093 D 16466.00 D Common Stock 2019-11-06 4 S false 15740.00 29.7497 D 726.00 D Common Stock 2019-11-06 4 S false 726.00 30.84 D 0.00 D Stock Option (right to buy) 6.61 2019-11-06 4 M false 56542.00 0.00 D 2027-12-11 Common Stock 56542.00 87793.00 D Stock Option (right to buy) 7.60 2019-11-06 4 M false 9084.00 0.00 D 2028-03-05 Common Stock 9084.00 28612.00 D These trades were made pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $16.00 to $16.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $17.00 to $17.995. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $19.00 to $19.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $20.00 to $20.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $29.50 to $30.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This option was granted on December 12, 2017. The shares underlying the option are scheduled to vest as to 25% of the shares underlying the option on October 16, 2018, with the remainder vesting in equal quarterly installments through October 16, 2021. This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022. /s/ Emma Reeve 2019-11-08